Meridian Investment Counsel’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
SSWM
HWAM
DA
MWM
CFO
BRWA
CC
CCIA
BBWA
Meridian Investment Counsel's IBRX Position: Q3 2026 in Review
Meridian Investment Counsel held its ImmunityBio (IBRX) position steady in Q3 2026 at 96,433 shares worth $910K. The position accounts for 0.21% of the portfolio, ranked #112.
Meridian Investment Counsel first reported a position in IBRX in Q2 2020 and has held it in 26 quarters since. The position peaked at $2.29M in Q1 2021. 48 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Meridian Investment Counsel held 96,433 shares of ImmunityBio worth $910K as of Q3 2026.
- Meridian Investment Counsel left its ImmunityBio share count unchanged in Q3 2026.
- ImmunityBio made up 0.21% of Meridian Investment Counsel's portfolio in Q3 2026, its #112 holding.
- Meridian Investment Counsel first reported a position in ImmunityBio in Q2 2020 and has held it in 26 quarters since.
- Meridian Investment Counsel's ImmunityBio position peaked at $2.29M in Q1 2021.
- 48 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Meridian Investment Counsel's 13F filing for Q3 2026, filed 14 Oct 2026.